The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal year (FY) 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a […]
Read More
The Congressionally Directed Medical Research Programs (CDMRP) announces new FY24 Research Funding Opportunities spanning the research spectrum from mechanistic research to clinical trials and that are now available in Rare Disease research areas. More information: https://cdmrp.health.mil/funding/default. All organizations, institutions and companies, both international and domestic, are encouraged to apply.
Read MoreThe grant application submission deadline is coming up in just 2 months! The application submission deadline for this grant funding opportunity is February 13, 2024. Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) The purpose of this grant is to support efficient and innovative natural history studies that advance medical product development in rare […]
Read More
The Chan Zuckerberg Initiative (CZI) is expanding the Rare As One Network and a new cycle will be open next year (including for organisations outside the USA). A call for applications is now in effect. CZI has funded 2 Cycles so far, and learned how successfully patient organisations are engaging in research collaborations, generating significant […]
Read More
The US National Institutes of Health (NIH) published a new Notice of Funding Opportunity (NOFO) with the aim to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) for two or more disease indications, using the same genome editor, route of administration, and […]
Read More
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal year (FY) 2024 to support natural history studies for rare diseases and conditions. This funding opportunity is intended to support prospective or retrospective, efficient, and innovative natural history studies with a focus on collaborative […]
Read More
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a new […]
Read More
The Canadian Institute of Health Research – Institute of Genetics is pleased to announce the upcoming funding opportunity “National Pediatric Rare Disease Clinical Trials and Treatment Network”. The specific objectives of this funding opportunity are to: Develop a platform to support pediatric rare disease clinical trials in Canada; Increase the capacity to perform rare disease […]
Read More
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in […]
Read More